Exact Therapeutics As Stock Current Valuation
| EXTX Stock | NOK 3.78 0.06 1.56% |
Valuation analysis of Exact Therapeutics helps investors to measure Exact Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Exact Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Exact Therapeutics is based on 3 months time horizon. Increasing Exact Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Exact stock is determined by what a typical buyer is willing to pay for full or partial control of Exact Therapeutics AS. Since Exact Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Exact Stock. However, Exact Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.78 | Real 3.64 | Hype 3.78 | Naive 2.47 |
The intrinsic value of Exact Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Exact Therapeutics' stock price.
Estimating the potential upside or downside of Exact Therapeutics AS helps investors to forecast how Exact stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Exact Therapeutics more accurately as focusing exclusively on Exact Therapeutics' fundamentals will not take into account other important factors: Exact Therapeutics AS Company Current Valuation Analysis
Exact Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Exact Therapeutics Current Valuation | 432.68 M |
Most of Exact Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Exact Therapeutics AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Exact Therapeutics AS has a Current Valuation of 432.68 M. This is 96.99% lower than that of the Healthcare sector and 90.69% lower than that of the Biotechnology industry. The current valuation for all Norway stocks is 97.4% higher than that of the company.
Exact Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exact Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exact Therapeutics could also be used in its relative valuation, which is a method of valuing Exact Therapeutics by comparing valuation metrics of similar companies.Exact Therapeutics is currently under evaluation in current valuation category among its peers.
Exact Fundamentals
| Return On Equity | -0.46 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (844.98) % | |||
| Current Valuation | 432.68 M | |||
| Shares Outstanding | 30 M | |||
| Shares Owned By Insiders | 64.13 % | |||
| Shares Owned By Institutions | 26.24 % | |||
| Price To Book | 6.55 X | |||
| Price To Sales | 8,803 X | |||
| Gross Profit | 52 K | |||
| EBITDA | (56.66 M) | |||
| Net Income | (58.59 M) | |||
| Current Ratio | 15.66 X | |||
| Book Value Per Share | 2.60 X | |||
| Cash Flow From Operations | (55.11 M) | |||
| Earnings Per Share | (1.95) X | |||
| Beta | 0.21 | |||
| Market Capitalization | 359.97 M | |||
| Total Asset | 117.63 M | |||
| Net Asset | 117.63 M |
About Exact Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Exact Therapeutics AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exact Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exact Therapeutics AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Exact Stock
Exact Therapeutics financial ratios help investors to determine whether Exact Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Exact with respect to the benefits of owning Exact Therapeutics security.